FDA Diabetes Drug Inquiry Finds No Cancer Risks

Law360, New York (July 31, 2013, 5:57 PM EDT) -- The U.S. Food and Drug Administration said Wednesday it has found no evidence that a class of diabetes drugs made by Merck & Co. Inc., Bristol-Myers Squibb Co. and others is linked to pancreatic cancer, after European regulators closed a parallel probe last week.

The FDA said it concurs with the European Medicines Agency, which determined on Friday that available data does not confirm recent concerns that a class of type 2 diabetes drugs called incretin mimetics carry an increased risk of pancreatic cancer. The FDA's own...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.